about
Need for standardization of 18F-FDG PET/CT for treatment response assessmentsPositron emission tomography to assess hypoxia and perfusion in lung cancerWidespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injuryImaging biomarker roadmap for cancer studiesOff-line motion correction methods for multi-frame PET data.CT-perfusion versus [(15)O]H2O PET in lung tumors: effects of CT-perfusion methodology.Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures.Accuracy and precision of pseudo-continuous arterial spin labeling perfusion during baseline and hypercapnia: a head-to-head comparison with ¹⁵O H₂O positron emission tomography.Quality control for quantitative multicenter whole-body PET/MR studies: A NEMA image quality phantom study with three current PET/MR systems.Quantitative agreement between [(15)O]H2O PET and model free QUASAR MRI-derived cerebral blood flow and arterial blood volume.Impact of scar on water-perfusable tissue index in chronic ischemic heart disease: Evaluation with PET and contrast-enhanced MRI.Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study.Investigation of practical initial attenuation image estimates in TOF-MLAA reconstruction for PET/MR.NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).Standards for PET image acquisition and quantitative data analysis.Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities.Subtle alterations in cerebrovascular reactivity in mild cognitive impairment detected by graph theoretical analysis and not by the standard approachImage-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28Partial volume correction strategies for quantitative FDG PET in oncology.Prediction of functional recovery after revascularization in patients with chronic ischemic myocardial dysfunction: perfusable tissue index by positron emission tomography and contrast-enhanced MRI comparison study.Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion.In vivo validation of reconstruction-based resolution recovery for human brain studies.Integration of FDG-PET/CT into external beam radiation therapy planning: technical aspects and recommendations on methodological approaches.Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancerKinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function.Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.Neurophysiological effects of sleep deprivation in healthy adults, a pilot study.FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.Day-to-day test-retest variability of CBF, CMRO2, and OEF measurements using dynamic 15O PET studies.Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studiesRetrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trialMetabolically active tumour volume segmentation from dynamic [(18)F]FLT PET studies in non-small cell lung cancer.Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients.Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology.The perfusable tissue index: a marker of myocardial viability.Reproducibility of quantitative (R)-[11C]verapamil studies.Measurement of metabolic tumor volume: static versus dynamic FDG scans
P50
Q26998501-2C4D17B9-6592-4ACC-9F92-CCAA309F8A56Q27026940-4A057AB9-CD1F-44D6-9875-B86469ADD70EQ28243395-2A5EE8C7-7801-4CA3-AE8B-1740DC44C27AQ30242020-D9F3B0A2-F7D3-4D27-9F8E-BDC97E65EA58Q30491744-E7370309-81CF-456E-8761-56DD598B4C4AQ30620750-4A3626C4-594D-4BA4-85F8-61426B6D6878Q30645097-0B5BCD37-A18E-4A1C-A87C-FEA48F4D717CQ30757748-B8845024-7BA6-4A84-930E-1A373190D479Q31000575-E7FF5C9C-98E3-4894-A80F-D40E62E93222Q31045631-E369F51E-CE2B-43AE-BC90-476F5A5E4662Q31045880-6C6D0B7E-801D-403A-866C-161F588CF1A6Q31049621-950CF54E-7979-49D8-AB17-C7F4F4C78BEAQ31111878-7A7E5AA8-8958-4F8A-815A-415273F41903Q33356751-1698BE2C-A917-4726-94AC-05BE2959F116Q33432463-A31ADE41-EA29-4CB9-9BE2-017D7A2B74ADQ33620499-15AB500C-C24D-4399-8EC5-43F03516078CQ33676184-29240C2F-095F-4BA9-A719-C07C28905533Q33833784-6F8185D7-7D9C-417E-B6CD-21446CEB27F3Q34054615-9A578AE6-5B9A-4A3C-A224-381DAA8F87EEQ34063955-FFC4C2AE-D83E-4FAB-9F1E-A5AA37224D4EQ34170769-ED79D07C-A4B9-451C-B20F-185535F35D02Q34170801-F16691E1-B031-423B-8A03-FA8AFE189632Q34219336-20EF580C-6E9B-47F7-B11D-8E9B165EE57AQ34465066-0C93115A-9B7A-41C2-B28F-9070C12CF9B4Q34518228-2B858824-1761-4876-8256-A8262D31D6F4Q34544677-39FE580A-DC0F-4D22-9CEB-A2B5D93EC324Q34744444-875E038E-553C-4E96-B749-C2C046A33488Q34757048-CC31D227-AE4F-41A7-8E3C-2B4BD9714713Q34860276-FFE86C28-1D45-497D-9E4F-8EAED5A6A75EQ34995321-22EF6684-3612-4F61-9095-46C01553027FQ35043725-B2B866CF-ED53-4FDE-8990-63ADAE453453Q35082624-D71ED80C-9446-448F-978F-127271D5E13FQ35151263-996155DA-5341-49E3-AA32-47476E2A0B12Q35244168-1BF25F06-90D0-43C1-8E67-BCB3DEA3C0E5Q35537570-7142AA1A-52A8-4D5B-ACB6-9EABA17EF780Q35572798-CA91248B-1D9D-4937-95D7-2A53CCEE2B79Q35586008-C5B95B53-50A8-434B-8165-B226F07B4ACEQ35605420-9A303C68-BE94-4F8F-9DC6-0FB93E30F200Q35742284-B88F7F69-BED6-49FB-8372-4A71A8EA8A3DQ35774813-DFAFDE5B-E35D-4BF5-AFF1-23B78630A892
P50
subject
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Ronald Boellaard
@ast
Ronald Boellaard
@en
Ronald Boellaard
@es
Ronald Boellaard
@nl
Ronald Boellaard
@sl
type
label
Ronald Boellaard
@ast
Ronald Boellaard
@en
Ronald Boellaard
@es
Ronald Boellaard
@nl
Ronald Boellaard
@sl
prefLabel
Ronald Boellaard
@ast
Ronald Boellaard
@en
Ronald Boellaard
@es
Ronald Boellaard
@nl
Ronald Boellaard
@sl
P1006
P214
P1006
P106
P21
P213
0000 0003 9138 8743
P214
P2456
P31
P496
0000-0002-0313-5686
P735
P7859
viaf-285197081